MLAB:NSD-Mesa Laboratories Inc (USD)

COMMON STOCK | Scientific & Technical Instruments |

Last Closing

USD 107.77

Change

-4.63 (-4.12)%

Market Cap

USD 0.62B

Volume

0.03M

Analyst Target

USD 271.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Scientific & Technical Instruments

Symbol Name Price(Change) Market Cap
TRMB Trimble Inc

-0.20 (-0.27%)

USD 14.95B
CGNX Cognex Corporation

-0.74 (-1.75%)

USD 6.93B
MKSI MKS Instruments Inc

-0.97 (-0.86%)

USD 6.77B
NOVT Novanta Inc

-4.54 (-2.60%)

USD 6.26B
ITRI Itron Inc

-1.96 (-1.62%)

USD 5.04B
ITRN Ituran Location and Control Lt..

-0.04 (-0.14%)

USD 0.53B
FARO FARO Technologies Inc

-0.86 (-3.11%)

USD 0.34B
MVIS Microvision Inc

-0.04 (-4.04%)

USD 0.23B
SOTK Sono-Tek Corp

+0.15 (+3.45%)

USD 0.07B
LUNA Luna Innovations Incorporated

+0.04 (+2.52%)

USD 0.06B

ETFs Containing MLAB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Scientific & Technical Instruments) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.86% 67% D+ 52% F
Dividend Return 0.46% 25% F 8% B-
Total Return 3.32% 62% D 49% F
Trailing 12 Months  
Capital Gain 14.93% 73% C 60% D-
Dividend Return 0.68% 25% F 8% B-
Total Return 15.61% 73% C 58% F
Trailing 5 Years  
Capital Gain -55.37% 35% F 24% F
Dividend Return 1.33% 25% F 4% F
Total Return -54.04% 35% F 24% F
Average Annual (5 Year Horizon)  
Capital Gain -14.64% 18% F 16% F
Dividend Return -14.35% 18% F 16% F
Total Return 0.29% 25% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 24.87% 100% F 70% C-
Risk Adjusted Return -57.72% 18% F 12% F
Market Capitalization 0.62B 74% C 64% D

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.